Cellular antiseizure mechanisms of everolimus in pediatric tuberous sclerosis complex, cortical dysplasia, and non–mTOR‐mediated etiologies
Authors:
Open Access
- 2 September 2018
- journal article
- research article
- Published by Wiley in Epilepsia Open
- Vol. 3 (S2) , 180-190
Abstract
Summary: The present study was designed to examine the potential cellular antiseizure mechanisms of everolimus, a mechanistic target of rapamycin (mTOR) pathway blocker, in pediatric epilepsy cases. Cortical tissue samples obtained from pediatric patients (n = 11, ages 0.67–6.75 years) undergoing surgical resections for the treatment of their pharmacoresistant epilepsy were examined electrophysiologically in ex vivo slices. The cohort included mTOR‐mediated pathologies (tuberous sclerosis complex [TSC] and severe cortical dysplasia [CD]) as well as non–mTOR‐mediated pathologies (tumor and perinatal infarct). Bath application of everolimus (2 μm) had practically no effect on spontaneous inhibitory postsynaptic activity. In contrast, long‐term application of everolimus reduced spontaneous excitatory postsynaptic activity, burst discharges induced by blockade of γ‐aminobutyric acid A (GABAA) receptors, and epileptiform activity generated by 4‐aminopyridine, a K+ channel blocker. The antiseizure effects were more pronounced in TSC and CD cases, whereas in non–mTOR‐mediated pathologies, the effects were subtle at best. These results support further clinical trials of everolimus in mTOR pathway–mediated pathologies and emphasize that the effects require sustained exposure over time.Keywords
Funding Information
- Novartis (RAD001MUS246T)
- University of California, Los Angeles
This publication has 46 references indexed in Scilit:
- Tuberous sclerosis complex2018
- Game of TOR — The Target of Rapamycin Rules Four KingdomsNew England Journal of Medicine, 2017
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 studyThe Lancet, 2016
- Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study programArchives of Gynecology and Obstetrics, 2015
- Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complexNeuro-Oncology, 2015
- Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trialThe Lancet, 2013
- Immunosuppressant Neurotoxicity in Rat Brain Models: Oxidative Stress and Cellular MetabolismChemical Research in Toxicology, 2010
- Rapamycin and tuberous sclerosis complex: From Easter Island to epilepsyAnnals of Neurology, 2008
- Rapamycin causes regression of astrocytomas in tuberous sclerosis complexAnnals of Neurology, 2006
- Structure of the FKBP12-Rapamycin Complex Interacting with Binding Domain of Human FRAPScience, 1996